SMARCA4-deficient Primary CNS Malignant Tumors
1 clinical trials · Condition
◉ Watch SMARCA4-deficient Primary CNS Malignant Tumors
| Record | Firm | Date |
|---|---|---|
| Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors (NCT05407441) | Susan Chi, MD | 2023-08-10 |
Track SMARCA4-deficient Primary CNS Malignant Tumors automatically
Every clearance here is in the API, with alerts when new ones post.